Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune Diseases
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has
presented data on ES210, one of its bispecific ADAPTIRTM
(Modular Protein Technology) molecules, that is targeting autoimmune
disease at Keystone Symposia’s Advances in the Knowledge and Treatment
of Autoimmunity in Whistler, British Columbia, Canada.
The ES210 molecule was engineered using Emergent’s ADAPTIR technology
platform and contains binding sites specific for CD86 coupled to a
monomeric form of IL-10 known to confer immunosuppressive activity.
The poster, entitled “A Bispecific ADAPTIR™ Molecule That Targets
CD86 and Delivers IL-10 Inhibits Antigen Presenting Cells and Has
Potential as a Therapeutic Treatment of Autoimmune Disease,” presented
pre-clinical data showing that ES210 displays high levels of in
vitro and in vivo potency in blocking T-cell proliferation in
human mixed lymphocyte reactions and in a humanized graft-versus-host
disease model. Dendritic cells play a central role in the generation and
regulation of immunity; therefore, targeting dendritic cell function
represents a therapeutic opportunity to suppress immunopathological
processes in autoimmune disease.
“Emergent is investigating an ADAPTIR molecule that targets and blocks
the co-stimulatory receptor CD86, while delivering the immunosuppressive
cytokine IL-10 to CD86-expressing antigen presenting cells,” said Jane
Gross, Ph.D., vice president of applied research at Emergent
BioSolutions. “We are pleased to present the study results, which show
the ADAPTIR molecule as having potential applications in the treatment
of transplant rejection as well as autoimmune and inflammatory diseases
such as Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.”
About the ADAPTIR™ Platform
ADAPTIR bispecific proteins are modular, single chain polypeptides that
comprise two separate binding domains (VL and VH), a hinge segment, and
an effector domain (huFc). They have a differentiated structure from
monoclonal antibodies and can generate a unique signaling response. In
addition, ADAPTIR proteins may mediate complement dependent cytotoxicity
and Fc dependent cytotoxicity, similar to monoclonal antibodies.
ADAPTIR is the new trademark for Emergent BioSolutions Inc.’s modular
protein technologies that were previously identified using the SCORPIONTM
(multispecific protein therapeutic) and SMIPTM (monospecific
protein therapeutic) trademarks. ADAPTIR and any and all Emergent
BioSolutions Inc. brand, product, service and feature names, logos and
slogans are trademarks or registered trademarks of Emergent BioSolutions
Inc. or its subsidiaries in the United States or other countries. All
rights reserved.
About Emergent BioSolutions
Emergent BioSolutions is a specialty pharmaceutical company seeking to
protect and enhance life by offering specialized products to healthcare
providers and governments to address medical needs and emerging health
threats. Additional information may be found at www.emergentbiosolutions.com.
Follow us on twitter: @emergentbiosolu.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, are
forward-looking statements. Forward-looking statements in this press
release include statements about the potential and therapeutic
opportunity of the ADAPTIR molecule. These forward-looking statements
are based on our current intentions, beliefs and expectations regarding
future events. We cannot guarantee that any forward-looking statement
will be accurate. Investors should realize that if underlying
assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could differ materially from our
expectations. Investors are, therefore, cautioned not to place undue
reliance on any forward-looking statement. Any forward-looking statement
speaks only as of the date of this press release, and, except as
required by law, we do not undertake to update any forward-looking
statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s
actual results to differ materially from those indicated by such
forward-looking statements, including the success of our ongoing and
planned preclinical studies and clinical trials; the rate and degree of
market acceptance and clinical utility of our products; the timing of
and our ability to obtain and maintain regulatory approvals for our
product candidates; and our commercialization, marketing and
manufacturing capabilities and strategy. The foregoing sets forth many,
but not all, of the factors that could cause actual results to differ
from our expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in our periodic reports filed with the SEC, when evaluating
our forward-looking statements.
